NewAmsterdam Pharma Company N.V. Board of Directors
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.
Founder, Chief Scientific Officer, Member of Executive Board & Director
Leaving Board of Directors Review
Your about to visit the following url
Invalid URL
Loading...
Comments
Comment created.